Randomized controlled trial· 2019

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Kingsberg SA, Clayton AH, Portman D, et al.

Obstetrics & Gynecology

PubMed
31599840
Evidence level
high
Verification
verified

Summary

Two phase 3 trials of bremelanotide in premenopausal women with HSDD.

Limitations

Population and indication were specific; results cannot be generalized to all libido concerns.

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.